Browsing Tag
Crohn’s disease
11 posts
AbbVie’s SKYRIZI wins FDA approval for ulcerative colitis treatment
The U.S. Food and Drug Administration (FDA) has approved SKYRIZI (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor developed by AbbVie,…
June 19, 2024
AbbVie to acquire Landos Biopharma to bolster autoimmune disease treatments
AbbVie Inc. (NYSE: ABBV) and Landos Biopharma, Inc. (NASDAQ: LABP) have announced a landmark agreement, marking a strategic…
March 25, 2024
Eli Lilly’s mirikizumab triumphs in Phase 3 Crohn’s disease study
Eli Lilly and Company (NYSE: LLY), a pharmaceutical leader, unveiled that mirikizumab, its cutting-edge interleukin-23p19 antagonist, has demonstrated…
October 14, 2023
Merck to acquire biotech company Prometheus Biosciences for $10.8bn
Merck has agreed to acquire Prometheus Biosciences, a Nasdaq-listed clinical-stage biotechnology company, in an all-cash deal worth around…
April 16, 2023
Crohn’s disease diet plan | What foods should be avoided by Crohn’s patients
In this post let us know about Crohn’s disease diet plan. What foods should be taken and what…
February 22, 2023
Crohn’s disease diagnosis and treatment
How is Crohn’s disease diagnosed? Crohn’s disease cannot be identified by any single test. The physician will start…
February 22, 2023
What is Crohn’s disease – symptoms and causes
What is Crohn’s disease? How common is Crohn’s disease? Crohn’s disease is a form of inflammatory bowel disease…
February 22, 2023
AzurRx BioPharma acquires US biotech company First Wave Bio for $229m
AzurRx BioPharma has signed a stock and cash deal worth $229 million to acquire Florida-based clinical-stage biotech company…
September 14, 2021
Amgen submits BLA for Infliximab biosimilar ABP 710 to FDA
Amgen Inc. has officially submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA)…
December 18, 2018
Mylan launches Hulio, a biosimilar to Humira, across major European markets
Mylan has officially launched Hulio, its biosimilar to AbbVie’s Humira (adalimumab), across major European markets. This launch follows…
October 22, 2018